Pharmacodynamics and Safety of a New Calcium Sensitizer, Levosimendan, and Its Metabolites during an Extended Infusion in Patients with Severe Heart Failure

Journal of Clinical Pharmacology - Tập 42 Số 1 - Trang 43-51 - 2002
Matti Kivikko1,2, Saila Antila2, Jaan Eha3, Lasse Lehtonen1, Pertti J. Pentikäinen4
1Department of Clinical Pharmacology, University of Helsinki, Finland
2Orion Pharma, Clinical Research, Cardiovascular Projects, Espoo, Finland
3Mustamäe Hospital, Tallinn, Estonia.
4Helsinki University Central Hospital, Department of Internal Medicine, Helsinki, Finland.

Tóm tắt

Levosimendan is a new calcium sensitizer developed for the short‐term intravenous treatment of congestive heart failure. The aims of the present open‐label, nonrandomized study were to determine the tolerability, hemodynamic effects, and the basic pharmacokinetics of levosimendan and its metabolites during an extended continuous infusion of levosimendan. Twenty‐four patients with New York Heart Association (NYHA) III‐IV heart failure in two groups of 12 patients were exposed to either 0.05 μg/kg/min or 0.1 μg/kg/min of levosimendan for 7 days. Heart rate and blood pressure were measured, and blood samples for the determination of plasma concentrations of the parent drug and its metabolites were drawn daily during the infusion and the 10 to 15 days' follow‐up. The 7‐day infusion was well tolerated and no premature discontinuations occurred. Both systolic and diastolic blood pressure decreased maximally by 6 mmHg in the lower and by 11 mmHg in the higher levosimendan dose groups during the infusion period (p < 0.05 for both groups). The mean heart rate values increased maximally by 18 and 26 beats/min in the lower and higher levosimendan dose groups, respectively (p < 0.001 for both groups). The hemodynamic effects peaked at the end of the infusion period and thereafter slowly declined during the follow‐up. After the recommended infusion period of 24 hours, the mean heart rate increase was only 2 and 6 beats/min in the lower and higher levosimendan dose groups, respectively. The elimination half‐life of levosimendan was approximately 1 hour and of the metabolites 70 to 80 hours. It can be concluded that levosimendan, even administered considerably longer than the recommended 24 hours, was well tolerated. The 7‐day infusion induced a prolonged increase in heart rate and a minor decrease in blood pressure. The long‐lasting effects are probably explained by the active metabolite.

Từ khóa


Tài liệu tham khảo

10.1097/00000542-199410000-00025

10.1111/j.1476-5381.1995.tb17189.x

10.1016/S0008-6363(97)00057-6

10.1016/0022-2828(95)90009-8

Pollesello P, 1994, Binding of a new Ca2±‐sensitizer, levosimendan, to recombinant human cardiac troponin C, J Biol Chem, 269, 28584, 10.1016/S0021-9258(19)61945-9

10.1016/S0014-2999(97)01108-4

10.1211/0022357001773715

10.1016/S0002-9149(99)00314-8

10.1161/01.CIR.102.18.2222

10.1016/S0735-1097(00)00961-X

Follath F, 1999, Efficacy and safety of intravenous levosimendan in severe low‐output heart failure, Circulation, 18, I

Nieminen MS, 1999, Randomized study on safety and effectiveness of levosimendan in patients with left ventricular failure after an acute myocardial infarct, Circulation, 18, I‐646

10.1097/00005344-199506261-00008

10.1016/S0928-0987(99)00048-2

10.1111/j.1749-6632.1998.tb08288.x

10.1097/00005344-200007000-00016

10.1016/S0014-2999(00)00385-X

10.1161/01.CIR.94.12.3190

Bazett HC, 1920, An analysis of the time‐relations of electrocardiogram, Heart, 7, 353

10.1016/S0002-8703(99)70107-9

10.1016/S0002-9149(99)80725-5

10.1016/0002-8703(92)91013-Q

10.1016/0002-9149(92)90562-D

10.1097/00005344-200004000-00021

10.1016/S0002-9149(99)00310-0

Thông tin
Thông tin xuất bản

Journal of Clinical Pharmacology

Tập 42 Số 1

43-51

Thông tin tác giả